Evaluating Medical AI Tools as a Clinician

Most vendor claims rest on one headline metric, often the area under the ROC curve (AUC), measured on a dataset the vendor chose. That number answers a narrow question: how well the model ranks cases in that dataset. It says nothing about how the tool will behave with your patient mix, your documentation habits, your scanners or the alert threshold you would actually use. The gap can be large. A widely cited 2021 external validation of a proprietary sepsis prediction model, published in JAMA Internal Medicine, found much weaker discrimination than the developer had reported. The model missed many sepsis cases while still firing frequent alerts. A useful evaluation covers five areas. Validation data. Where did the training and test data come from? Were the test sites separate from the training sites? Was the study retrospective or prospective?; Local performance. Can you run the model silently on your own data and measure sensitivity, positive predictive value and calibration at your intended threshold?; Bias. Are results reported by age, sex, race and ethnicity, language, insurance and device type? How were underrepresented groups handled?; Regulatory status. Is the product FDA-cleared or approved, and for which indication? Or does the vendor say it is non-device clinical decision support?; and monitoring. Who watches performance after go-live? How will drift be detected? What happens when the vendor updates the model?. A common misconception is that FDA clearance proves a tool improves outcomes. Most AI devices reach the market through the 510(k) pathway, which requires showing substantial equivalence to an existing device. Many of these submissions include little prospective or multisite evidence. Another misconception is that a high AUC guarantees usefulness. For a rare condition, even an accurate model can produce mostly false alarms. Clearance and published accuracy are where an evaluation starts, not where it ends.